Drug Approval | July 05, 2024
Briefs: Alembic Pharmaceuticals and Relonchem
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Imfinzi also recommended for patients with mismatch repair deficient disease
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Subscribe To Our Newsletter & Stay Updated
